Gallium Scan Predicts Activity Of Diffuse Parenchymal Lung Disease

A Huaringa, J Barriga, F Leyva, R Lainez, A Darwish, Delpasand, J Ro

Abstract

The first step in the evaluation of diffuse parenchymal lung disease (DPLD) should be to establish its activity. The currently accepted parameters are clinical grounds, changes in lung physiology, computerized tomographic (CT) appearance, and lung biopsy. Gallium 67 scintigraphy has been felt to be controversial.

We reviewed 17 cases of DPLD and documented gallium 67 scan results with evidence of activity as reflected by 10% change in pulmonary function tests, evidence of alveolitis on CT and cellular proliferation on lung biopsies.

Fourteen cases had positive Gallium scans and active DPLD (true positives), one had positive scan and active DPLD (false positive), and one had negative scan and active DPLD (false negative), and one had a negative scintigraphy and no evidence of activity (true negative).

The sensitivity of the gallium 67 scan was 93%, the specificity was 50%, the positive predictive value was 93%, negative predictive value was 50%, the likelihood ratio for positive was 1.86, and the negative likelihood was 0.13.

Gallium scan results were also correlated with a clinical, radiological, physiological, pathological score (CRPP), yielded a p value of 0.058.

We conclude that the gallium 67 scintigraphy is a useful method to establish inflammatory activity in DPLD.

ABBREVIATIONS

Diffuse parenchymal lung disease (DPLD), computerized tomography (CT), pulmonary function tests (PFT’s), clinical, radiological, physiological, pathological (CRPP) score, Interstitial Lung Diseases (ILD), Idiopathic Pulmonary Fibrosis (IPF), British Thoracic Society (BTS), Cryptogenic fibrosing alveolitis (CFA), polymorphonuclears cells (PMNs),

INTRODUCTION

Diffuse parenchymal lung disease (DPLD) is a common denominator term given to a heterogeneous group of clinical entities that can cause mainly dyspnea and hypoxemia. It does not only affect the interstitium but also the alveolar space and sometimes it may even involve the airways. The first step in the evaluation of DPLD should be to establish its activity. The currently accepted parameters are clinical grounds, changes in lung physiology, computerized tomography (CT) appearance, and lung biopsy. However clinical grounds are somewhat subjective; the chest-X-rays have low sensitivity (j) (p); pulmonary function tests (PFT’s) have a limited reproducibility, but a proportion of patients have preserved lung volumes or airflow obstruction, such abnormalities should not lead to the exclusion for a diagnosis of DPLD (k) (p); CT Scan of the chest is better than plain radiographs, clinicians are significantly more likely to determine the correct diagnosis for DPLD, the extent of the disease, and the optimal site for biopsy, but its interpretation requires special training and yet the reading may be somewhat subjective (l) (p). Histopathologically, the lungs of patients with DPLD can show from predominantly inflammatory pattern with little or no fibrosis (alveolitis), to predominantly fibrotic pattern or no inflammation. Lung biopsy is the goal standard, but it depends on type, size, and site of the sample, some DPLDs show overlapping histological features (m), (p) and repetitive lung biopsy is not feasible (s). It is important to determine the status of a particular patient on this spectrum.; Gallium 67 scintigraphy has been felt to be controversial despite that in 1969 it was described as a good marker in inflammatory lesions © (e) Gallium scan has become increasingly used to evaluate the presence of alveolitis in DPLD and to stage the disease process (n) (q) due to the fact that the concentration of gallium in the lung is normally low, making abnormal uptake of gallium easily recognizable (o). We decided to study the ability of Gallium-67 scanning to predict alveolitis
by means of correlating with a correlated clinical, radiological, physiological, pathological (CRPP) score.

**METHODS**
A retrospective review of cases referred to the Pulmonary Clinic of University of Texas M. D. Anderson Cancer Center with Diffuse Parenchymal Lung Disease and have had Gallium-67 Scan, CT Scan of the Chest, PFT's and lung biopsy.

Results of Gallium we reported as positive or negative. Radiographic Score was based on CT Chest appearance: 1 = Alveolitis (Ground glass) and 0 = Fibrosis.

Physiology Score: 1 = 10% in Total lung capacity (TLC) or Diffusion of CO2 (DLCO2), 0 = No change.

Pathologic Score: 1 = Cellularity, 0 = Fibrosis

Clinic Radiological Physiologic Pathologic Score CPRP + Summa of Rad + Physiologic + Pathologic score using an aseptic technique the ETTS were removed from 55 patients from the intensive care unit (ICU) at University of Texas M. D. Anderson Cancer Center.

**RESULTS**
Seventeen patients were included in the study. The Gallium scan was positive in 15 of them. The sensitivity of the Gallium-67 was 93%, the specificity was 50%, of the positive predictive value was 1.86 and for negative 0.13. The correlation of Gallium Scan with the scores as shown in the figures.

We had fourteen cases Gallium Scan positive and active DPLD (true positive), one had positive scan and no evidence of activity (false positive), one had negative scan and active DPLD (false negative), and one had negative scintigraphy and no evidence of activity (true negative). The sensitivity of the gallium 67 scan was 93%, the specificity was 50%, the positive predictive value was 93%, the negative predictive value was 50%, the likelihood ratio for positive was 1.86, and the negative likelihood ratio was 0.13.

Gallium scan results were also correlated with a clinical, radiological, physiological, pathological (CRPP) score, yielding a p value of 0.058.

**DISCUSSION**
Gallium has been prejudiced to be unable to predict the clinical course or prognosis in Interstitial Lung Diseases (ILD) such Sarcoidosis and Idiopathic Pulmonary Fibrosis (IPF), the British Thoracic Society (BTS) care committee (p) conclude that the pulmonary parenchyma may be positive in a wide range of DPLDs and, in this context gallium scanning is not helpful, furthermore serial gallium scans are not useful as monitors of disease in Cryptogenic fibrosing alveolitis (CFA); although Vanderstappen et al @ described that the gallium-67 scanning is useful in the management of CFA and hypersensitivity pneumonitis.

Others have found that there was a strong correlation between the intensity of gallium uptake in pulmonary parenchyma and the detection rate of granuloma. Line et al (b) evaluated the extent and relative activity of the inflammatory process using gallium-67, they correlationated the gallium scan with the degree of interstitial cellularity and the degree of alveolar cellularity, Lavender (i) observed that gallium-67 could concentrate in the area of active inflammation and could be used as the tracer of activity. In fact, in Sarcoidosis, Tuberculosis, and Bronchocarcinoma gallium scan has been proven to be very useful in predicting disease activity(a) (f). The biodistribution of the radionuclides of gallium shows an affinity for malignancies and inflammatory process, but it is affected by sex hormone status, age, lactation, radiotherapy, chemotherapy (c) (f) and steroid treatment (g).

The physical and chemical characteristics of Gallium are similar to ferrum, it combines with the lactoferrin of inflammatory cells, most likely taken up by activated alveolar macrophages or polimorphonuclears cells (PMNs) the areas of inflammation, and the uptake may be a marker of alveolitis (a) (b). This is supported by the finding of a better correlation of gallium uptake with the extent of inflammation on open lung biopsy (d) (h) . Although it is nonspecific, it is very sensitive marker for the presence of inflammation, but it depends on the number of leukocytes, so it is not sensitive in leukopenic patients (q).

These observations indicate that the intensity of gallium uptake reflects mainly the degree of granuloma formation in the lung, and gallium scintigraphy may be an indicator for predicting the degree of activity of pulmonary disease; Siemsen et al (f) observed that in the earlier stages, the inflammatory process is best followed by 67Gallium citrate scanning. It is observed that the presence of activity decreased after using steroids, these changes correlated well with clinical improvements (a).

**CONCLUSIONS**
This study showed that 67Ga-citrate scan may serve as a
study complementary to chest radiography because it indicates the extent, localization, and degree of activity of the inflammatory disease with greater accuracy than do the radiographic studies. It also permits the physicians to follow progression of the disease or response to treatment and possible to detect disseminated interstitial disease not visualized on radiographs.

Because Gallium scan is noninvasive, simple to perform, and widely available, it should prove useful to stage the activity of DPLD and to make decisions regarding therapy directed against the alveolitis component of the disease.

We conclude that gallium 67 scintigraphy is a useful method to establish inflammatory activity in DPLD.

CORRESPONDENCE TO

Armando Huaringa MD, MHA, FACP, FCCP Associate Professor of Medicine Loma Linda University School of Medicine White Memorial Medical Center 1720 Cesar Chavez Ave. Los Angeles, CA 90033 E-mail: huaringa@sbcglobal.net Telephone: 714-256-1420

References

Gallium Scan Predicts Activity Of Diffuse Parenchymal Lung Disease

Author Information
Armando Huaringa, MD, FCCP
Department of Pulmonary Medicine, The University of Texas M. D. Anderson Cancer Center

J. C. Barriga, MD
Department of Pulmonary Medicine, The University of Texas M. D. Anderson Cancer Center

F. J. Leyva, MD
Department of Pulmonary Medicine, The University of Texas M. D. Anderson Cancer Center

R. Laínez, MD
Department of Pulmonary Medicine, The University of Texas M. D. Anderson Cancer Center

Amr Darwish, MD
Department of Pulmonary Medicine, The University of Texas M. D. Anderson Cancer Center

Delpasand, MD
Department of Nuclear Medicine, The University of Texas M. D. Anderson Cancer Center

J. Ro, MD
Department of Pathology, The University of Texas M. D. Anderson Cancer Center